Serum platelet-derived growth factor-BB levels as a potential biomarker in assessing the metabolic activity of lesions in alveolar echinococcosis patients

Abstract ObjectiveAlveolar echinococcosis (AE) is a chronic disease caused by the larval stage of Echinococcus multilocularis. Assessing the metabolic activity of AE lesions is critical to evaluate disease progression and survey treatment options. There is an urgent need to identify more rapid, convenient, and non-invasive clinical detection methods to substitute the current techniques. Herein, we evaluated the viability of platelet-derived growth factor-B B (PDGF-BB) as a biomarker for detecting the metabolic activity of AE patients. Concentration of serum PDGF-BB homodimers (sPDGF-BB) was assessed via ELISA. Correlations of PDGF-BB expression levels with clinicopathological features of AE patients were analyzed using SPSS. ResultsThe concentrations of sPDGF-BB were significantly lower in AE patients (p<0.0001), particularly in HMAE patients (p<0.05). The expression levels of PDGF-BB were significantly higher in CLT in AE patients (p<0.0001). We found that metabolically active AE and sPDGF-BB are significantly negatively correlated (r=-0.624, p=0.0004). Besides, the local expression levels of PGFD-BB was positively correlated with metabolic activity, the PNM stage, and lesion size. Notably, the sPDGF-BB levels were proposed as a potential biomarker for assessing metabolic activity of AE, with 85.7% sensitivity and 81% specificity (95% confidence interval, P = 0.003).

Download Full-text

Serum platelet-derived growth factor-BB levels as a potential biomarker in assessing the metabolic activity of lesions in alveolar echinococcosis patients

10.21203/rs.3.rs-37213/v2 ◽

2020 ◽

Author(s):

ying ke ◽

Xiaojuan Bi ◽

Ning Yang ◽

Xiaohong Li ◽

Wenmei Ma ◽

...

Keyword(s):

Growth Factor ◽

Metabolic Activity ◽

Alveolar Echinococcosis ◽

Treatment Options ◽

Lesion Size ◽

Platelet Derived Growth Factor ◽

Detection Methods ◽

Expression Levels ◽

Non Invasive ◽

Potential Biomarker

Abstract Objective Alveolar echinococcosis (AE) is a chronic disease caused by the larval stage of Echinococcus multilocularis. Assessing the metabolic activity of AE lesions is critical to evaluate disease progression and survey treatment options. There is an urgent need to identify more rapid, convenient, and non-invasive clinical detection methods to substitute the current techniques. Herein, we evaluated the viability of platelet-derived growth factor-B B (PDGF-BB) as a biomarker for detecting the metabolic activity of AE patients. Concentration of serum PDGF-BB homodimers (sPDGF-BB) was assessed via ELISA. Correlations of PDGF-BB expression levels with clinicopathological features of AE patients were analyzed using SPSS. Results The concentrations of sPDGF-BB were significantly lower in AE patients (p<0.0001), particularly in High Metabolically Active AE patients (HMAE) patients (p<0.05). The expression levels of PDGF-BB were significantly higher in close liver tissue (CLT) in AE patients (p<0.0001). We found that metabolically active AE and sPDGF-BB are significantly negatively correlated (r=-0.624, p=0.0004). Besides, the local expression levels of PDGF-BB was positively correlated with metabolic activity, PNM stage, and lesion size. Notably, the sPDGF-BB levels were proposed as a potential biomarker for assessing metabolic activity of AE, with 81% sensitivity and 85.7% specificity (95% confidence interval, p = 0.003).

Download Full-text

Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy

Frontiers in Immunology ◽

10.3389/fimmu.2020.594110 ◽

2021 ◽

Vol 11 ◽

Author(s):

Helen C. Steel ◽

W. D. Francois Venter ◽

Annette J. Theron ◽

Ronald Anderson ◽

Charles Feldman ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Growth Factor ◽

Platelet Activation ◽

Cd40 Ligand ◽

Platelet Derived Growth Factor ◽

Suppressive Therapy ◽

Control Group ◽

Soluble Cd40 Ligand ◽

Potential Biomarker ◽

Healthy Control

Systemic biomarkers of inflammation, including cytokines and chemokines, are potentially useful in the management of both HIV infection and non-AIDS-defining disorders. However, relatively little is known about the utility of measurement of circulating biomarkers of platelet activation as a strategy to monitor the efficacy of combination antiretroviral therapy (cART), as well as the persistence of systemic inflammation following virally-suppressive therapy in HIV-infected persons. These issues have been addressed in the current study to which a cohort consisting of 199 HIV-infected participants was recruited, 100 of whom were cART-naïve and the remainder cART-treated and virally-suppressed. Fifteen healthy control participants were included for comparison. The study focused on the effects of cART on the responsiveness of three biomarkers of platelet activation, specifically soluble CD40 ligand (sCD40L), sCD62P (P-selectin), and platelet-derived growth factor-BB (PDGF-BB), measured using multiplex suspension bead array technology. Most prominently sCD40L in particular, as well as sCD62P, were significantly elevated in the cART-naïve group relative to both the cART-treated and healthy control groups. However, levels of PDGF-BB were of comparable magnitude in both the cART-naïve and –treated groups, and significantly higher than those of the control group. Although remaining somewhat higher in the virally-suppressed group relative to healthy control participants, these findings identify sCD40L, in particular, as a potential biomarker of successful cART, while PDGF-BB may be indicative of persistent low-level antigenemia.

Download Full-text